Gavriilaki Eleni, Sakellari Ioanna, Chatzikonstantinou Thomas, Mallouri Despina, Batsis Ioannis, Katsifa Eleni, Papadimitriou Stergios, Panteliadou Alkistis, Baldoumi Eirini, Demosthenous Christos, Bousiou Zoi, Constantinou Varnavas, Sotiropoulos Damianos, Anagnostopoulos Achilles
Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Microbiology Department, G. Papanicolaou Hospital, Thessaloniki, Greece.
Front Med (Lausanne). 2021 Feb 4;7:608165. doi: 10.3389/fmed.2020.608165. eCollection 2020.
carbapenemase (KPC)-producing (KPC-Kp) emerge as a major healthcare concern worldwide. Despite the significance of infections before and after allogeneic hematopoietic cell transplantation (alloHCT), the burden of KP infections has not been extensively evaluated. We studied the incidence, risk factors, and outcomes of consecutive alloHCT recipients with Kp isolates before and after alloHCT. Among 424 patients who underwent alloHCT in 2008-2018, we studied two groups: those with Kp isolates before (group 1, 52 patients) and those with Kp isolates after alloHCT (group 2, 66 patients). prE-transplant infections were associated with post-transplant infections ( = 0.010), despite secondary prophylaxis. KPC-Kp was isolated in 29% of group 1, and 80% of group 2. Both groups were characterized by a significant burden of moderate-severe acute graft- vs.-host disease (GVHD) [cumulative incidence (CI) of 44.5 and 61.9%, respectively] and severe chronic (CI of 56.7 and 61.9%). Kp infections and GVHD were independent predictive factors of treatment-related mortality (TRM) in both groups. Our study highlights the significant impact of Kp infections on TRM, with GVHD consisting an important underlying factor. As prophylactic measures did not improve rates of post-transplant infections, innovative interventions need to be further investigated to address this major healthcare concern.
产碳青霉烯酶(KPC)的肺炎克雷伯菌(KPC-Kp)已成为全球医疗保健领域的主要关注点。尽管异基因造血细胞移植(alloHCT)前后感染的重要性,但肺炎克雷伯菌感染的负担尚未得到广泛评估。我们研究了alloHCT前后连续的alloHCT受者肺炎克雷伯菌分离株的发生率、危险因素和结局。在2008年至2018年接受alloHCT的424例患者中,我们研究了两组:alloHCT前有肺炎克雷伯菌分离株的患者(第1组,52例)和alloHCT后有肺炎克雷伯菌分离株的患者(第2组,66例)。尽管进行了二级预防,但移植前感染与移植后感染相关(P = 0.010)。第1组29%和第2组80%分离出KPC-Kp。两组的特征均为中重度急性移植物抗宿主病(GVHD)负担较重[累积发生率(CI)分别为44.5%和61.9%]以及重度慢性GVHD(CI分别为56.7%和61.9%)。肺炎克雷伯菌感染和GVHD是两组治疗相关死亡率(TRM)的独立预测因素。我们的研究强调了肺炎克雷伯菌感染对TRM的重大影响,GVHD是一个重要的潜在因素。由于预防措施未能提高移植后感染率,需要进一步研究创新干预措施来解决这一主要医疗保健问题。